Is Aktis Oncology, Inc. (AKTS) Overvalued?
We dive into why Aktis Oncology, Inc. (AKTS) could be considered overvalued on 2026-08-17, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
What You Need to Know About Aktis Oncology, Inc.'s Q3 Earnings
Aktis Oncology, Inc.'s fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (AKTS) missed or beat analyst's expectations.Michael Rose
Why Aktis Oncology, Inc.’s (AKTS) Stock Is Down 6.92%
As of Monday, July 13, Aktis Oncology, Inc.’s AKTS share price has dipped by 6.92%, which has investors questioning if this is right time to buy.Michael Rose
Why Aktis Oncology, Inc.’s (AKTS) Stock Is Up 5.42%
As of Tuesday, July 07, Aktis Oncology, Inc.’s AKTS share price has surged by 5.42%, which has investors questioning if this is right time to sell.Michael Rose
Why Aktis Oncology, Inc.’s (AKTS) Stock Is Down 12.19%
As of Monday, July 06, Aktis Oncology, Inc.’s AKTS share price has dipped by 12.19%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | AKTS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,338.8 | $292.6 | 48% |
|
| Shares Out (Mil) | 55.3 | 54.4 | 50% |
|
| Institutional Ownership | 98.9% | 93.2% | 83% |
|
| Float (Mil) | 28.6 | 40.2 | 35% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 209 | 544 | 44% |
|
| Price Change (52-week) |
na | 59.7% | na |
|
| Growth | AKTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 7 | 7 | |
| Current EPS | ($0.441) | ($1.648) | ($2.076) | |
| Month Ago EPS | ($0.457) | ($1.620) | ($1.967) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 2 | 2 | |
| Three Months Ago EPS | ($0.503) | ($1.625) | ($2.173) | |
| Year/Year Chg | 0.9% | (97.9%) | (96.5%) | |
| Financials | AKTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($73) | ($43) | 13% |
|
| EPS (TTM) | ($2.770) | ($1.400) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($75) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($46) | $2 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | AKTS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.75 | 2.83 | 61% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AKTS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (678.1%) | 64.2% | 0% |
|
| Net Margin | (727.0%) | (75.9%) | 1% |
|
| ROA | (26.2%) | (47.5%) | 18% |
|
| ROE | (36.8%) | (55.0%) | 18% |
|
| Liabilities to Assets | 13.0% | 29.6% | 8% |
|
| F-Score | 0 | 3 | na |
|
Aktis Oncology, Inc. did not pass any screens on 8/21/2026.
